Leuprorelin Acetate

Leuprorelin Acetate

Quick Details Description Light c gonadorelin acetate is a kind of common hormonal malignant tumor drug resistance, for the gonadotropic hormone releasing hormone (LHRH a decapeptide) nine peptide synthesis of analogues of light c gonadorelin acetate, LH and RH antagonists, LHRH is produced by...
Chat Now

Product Details

Quick Details

Product Name

Leuprorelin Acetate

CAS

74381-53-6

Molecular Formula

C59H84N16O12

Molecular Weight

1209.41

Appearance

White powder

Application

Hormone antitumor drugs

Purity

99%

storage

Short-term 2 ℃- 8 ℃, long - 20 ℃


Description



Light c gonadorelin acetate is a kind of common hormonal malignant tumor drug resistance, for the gonadotropic hormone releasing hormone (LHRH a decapeptide) nine peptide synthesis of analogues of light c gonadorelin acetate, LH and RH antagonists, LHRH is produced by the hypothalamus, suction release before it can cause pituitary gonadal hormone and follicle-stimulating hormone (FSH) and luteinizing hormone (LH) is generated. Because of its similar structure to LHRH, this product can also promote the release of FSH and LH after acting on the anterior pituitary, thus increasing the serum concentration of testosterone and dihydrotestosterone. It is clinically used for maintenance treatment of advanced prostate cancer, but after about 1 week of application of this product, the number of active receptors will decrease and gonadotropin secretion will also decrease. After 2 to 4 weeks, the concentration of testosterone and dihydrotestosterone can be reduced to the level of castration. When discontinued, gonadotropin and androgen can return to normal concentrations.

It is important to note that this product is not effective in oral administration and is well absorbed by hypodermic or muscle injection. The t1/2 outside the intestine was given for 3 h. No accumulative effect was observed in vivo, and the excretion rate of primary drugs and metabolites in urine was 2.9% and 1.5% respectively. Ethanol can enhance the effect of this product, the process of treatment should not drink alcohol, so as not to control adverse reactions. During the first week of treatment, the patient should be hospitalized as much as possible for monitoring. Experienced physicians should be selected to guide the medication to prevent serious neurological complications and urethral obstruction. The injection site should change frequently.


图片8

Inquiry